Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...
Moderna remains the most shorted stock among S&P 500 healthcare stocks in the last month of 2024
Short interest for healthcare stocks in S&P 500 rose slightly in December vs. November, while Moderna continued to be the most shorted stock of the month. The average short interest for S&P 500 Health ...
Moderna's Road To Stopping The Red
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Moderna’s Financial Outlook: Hold Rating Amidst Competitive Challenges and Strategic Adjustments
In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Moderna price target lowered to $38 from $70 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...